Physician profile
Robert J Kash
NPI 1740358126
$971.46
in general payments reported to CMS, 2019-2025
17 companies · $59.18 in 2025
The $59.18 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2022: $63.76 · 2023: $289 · 2024: $27.25 · 2025: $59.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.05 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $154.87 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $150.19 | 2019-2023 | Farxiga |
| Amgen INC. | $119.26 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $98.80 | 2019 | |
| Novo Nordisk INC | $72.54 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $69.04 | 2019-2023 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $53.40 | 2019 | |
| Pfizer INC. | $36.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.79 | 2019 | |
| Amarin Pharma, INC. | $22.44 | 2019 | |
| Lilly USA, LLC | $20.87 | 2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $20.41 | 2019 | |
| Exact Sciences Corporation | $19.89 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $16.72 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.85 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.